What is the price target for CGTX stock?
10 analysts have analysed CGTX and the average price target is 3.57 USD. This implies a price increase of 388.97% is expected in the next year compared to the current price of 0.7301.
COGNITION THERAPEUTICS INC (CGTX) Forecast, Price Target & Analyst Ratings
NASDAQ:CGTX • US19243B1026
Current stock price
0.7301 USD
-0.35 (-32.4%)
At close:
0.7446 USD
+0.01 (+1.99%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for COGNITION THERAPEUTICS INC (CGTX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q1 / 2026
- EPS Estimate
- -$0.06
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$3.57
Upside
+ 388.97%
From current price of $0.73 to mean target of $3.57, Based on 10 analyst forecasts
Low
$3.03
Median
$3.57
High
$4.20
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
10 Wall Street analysts provided a forecast for the next 12 months for CGTX. The average price target is 3.57 USD. This implies a price increase of 388.97% is expected in the next year compared to the current price of 0.7301.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.00%
CGTX was analyzed by 10 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about CGTX.
In the previous month the buy percentage consensus was at a similar level.
CGTX was analyzed by 10 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-27 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-12-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-11-21 | B. Riley Securities | Reiterate | Buy -> Buy |
| 2025-11-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-06-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-21 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-02-26 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-12-19 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-12-19 | B. Riley Securities | Upgrade | Neutral -> Buy |
| 2024-12-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-15 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-11-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-31 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-06 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2024-08-01 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-07-30 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2024-07-02 | Rodman & Renshaw | Reiterate | Buy -> Buy |
| 2024-06-06 | Chardan Capital | Initiate | Buy |
| 2024-05-29 | HC Wainwright & Co. | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q1 / 2026
- EPS Estimate
- -$0.06
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 56.29%
- Number of Analysts
- 4
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 1,381.40% | N/A 108.16% | N/A 76.33% | N/A 66.76% | N/A 55.94% | |||||||
| EBITDA YoY % growth | -17.75M | -17.31M 2.48% | -28.51M -64.70% | -43.47M -52.47% | -50.628M -16.47% | -53.859M -6.38% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -17.83M | -17.41M 2.36% | -28.6M -64.27% | -43.55M -52.27% | -50.724M -16.47% | -53.966M -6.39% | N/A 20.94% | N/A -0.41% | N/A -141.91% | N/A -18.31% | N/A -2.83% | N/A 13.83% | N/A 64.13% | N/A 327.23% | N/A 224.31% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -0.91 45.60% | -0.86 5.49% | -0.87 -1.16% | -0.33 62.07% | N/A 15.00% | N/A -56.36% | N/A -48.84% | N/A 14.06% | N/A 14.55% | N/A 63.83% | N/A 288.24% | N/A 215.63% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.06 56.29% | -0.05 53.64% | -0.07 -10.50% | -0.09 -333.50% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-25.53%
EPS Next 5 Year
-7.75%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
COGNITION THERAPEUTICS INC / CGTX Forecast FAQ
Can you provide the consensus estimates for COGNITION THERAPEUTICS INC next earnings?
The consensus EPS estimate for the next earnings of COGNITION THERAPEUTICS INC (CGTX) is -0.06 USD and the consensus revenue estimate is 0 USD.
How do analysts rate COGNITION THERAPEUTICS INC (CGTX)?
The consensus rating for COGNITION THERAPEUTICS INC (CGTX) is 82 / 100 . This indicates that analysts generally have a positive outlook on the stock.